Harvard Bioscience won't go IPO with its regenerative organ transplant device subsidiary, Harvard Apparatus Regenerative Technology Inc. (HART). Instead it will spin off HART as a newly public company, effective Nov. 1. According to Harvard Bioscience president David Green, the spin-off will enable Holliston, Mass.-based Harvard Bioscience to renew a growth-by-acquisition strategy it has pursued over the past 17 years.